{"DataElement":{"publicId":"6117739","version":"1","preferredName":"Breast Carcinoma HER2/Neu Gene Expression Immunohistochemical Test HER2/Neu Gene Immunohistochemical Test Status","preferredDefinition":"Information related to the status of the breast carcinoma HER2/neu gene expression immunochemical test.","longName":"BRCA_HNEU_EXP_IMUHIST_STAT","context":"CCTG","contextVersion":"1","DataElementConcept":{"publicId":"6117731","version":"1","preferredName":"Breast Carcinoma HER2/Neu Gene Expression Immunohistochemical Test","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla._This gene plays a role in cellular proliferation and is involved in the oncogenic process through amplification and/or overexpression in several cancers._Typically involves transcription of genetically encoded information into an intermediary message (messenger RNA) and subsequent translation into a functional protein._A diagnostic test in which an antibody is used to link a cellular antigen specifically to a stain that can be seen with a microscope.","longName":"2475941v1.0:6117729v1.0","context":"CCTG","contextVersion":"1","ObjectClass":{"publicId":"2475941","version":"1","preferredName":"Breast Carcinoma","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002","longName":"C4872","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11C95199-159B-5C1E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-19","modifiedBy":"ONEDATA","dateModified":"2006-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6117729","version":"1","preferredName":"ERBB2 Gene Gene Expression Immunohistochemical Test","preferredDefinition":"This gene plays a role in cellular proliferation and is involved in the oncogenic process through amplification and/or overexpression in several cancers.:Typically involves transcription of genetically encoded information into an intermediary message (messenger RNA) and subsequent translation into a functional protein.:A diagnostic test in which an antibody is used to link a cellular antigen specifically to a stain that can be seen with a microscope.","longName":"C17756:C16608:C51944","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ERBB2 Gene","conceptCode":"C17756","definition":"This gene plays a role in cellular proliferation and is involved in the oncogenic process through amplification and/or overexpression in several cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Gene Expression","conceptCode":"C16608","definition":"Typically involves transcription of genetically encoded information into an intermediary message (messenger RNA) and subsequent translation into a functional protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunohistochemical Test","conceptCode":"C51944","definition":"A diagnostic test in which an antibody is used to link a cellular antigen specifically to a stain that can be seen with a microscope.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66E01D27-3967-19F9-E053-F662850AA564","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66E01D27-3978-19F9-E053-F662850AA564","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"TAYLORT","dateModified":"2018-11-26","changeDescription":"11/26/18 TT released/CWinch. 3/8/18 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6117733","version":"1","preferredName":"HER2/Neu Gene Immunohistochemical Test Status","preferredDefinition":"This gene plays a role in cellular proliferation and is involved in the oncogenic process through amplification and/or overexpression in several cancers._A diagnostic test in which an antibody is used to link a cellular antigen specifically to a stain that can be seen with a microscope._A condition or state at a particular time.","longName":"6117733v1.0","context":"CCTG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"5682944","version":"1","preferredName":"Unknown","longName":"5682944","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B0E12-9AE5-79DC-E053-F662850A0B75","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"GDEEN","dateModified":"2023-12-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66DD6F31-FA1B-12A4-E053-F662850AE423","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"3+","valueDescription":"HER2/Neu Expression by Immunohistochemistry 3+","ValueMeaning":{"publicId":"6117734","version":"1","preferredName":"HER2/Neu Expression by Immunohistochemistry 3+","longName":"6117734","preferredDefinition":"An immunohistochemical result of 3+ for HER2/Neu expression that is considered positive for expression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HER2/Neu Expression by Immunohistochemistry 3+","conceptCode":"C147527","definition":"An immunohistochemical result of 3+ for HER2/Neu expression that is considered positive for expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66DD6F31-FA27-12A4-E053-F662850AE423","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA_WA","dateModified":"2023-12-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66DD6F31-FA40-12A4-E053-F662850AE423","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"2+","valueDescription":"HER2/Neu Expression by Immunohistochemistry 2+","ValueMeaning":{"publicId":"6117735","version":"1","preferredName":"HER2/Neu Expression by Immunohistochemistry 2+","longName":"6117735","preferredDefinition":"An immunohistochemical result of 2+ for HER2/Neu expression that is considered equivocal for expression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HER2/Neu Expression by Immunohistochemistry 2+","conceptCode":"C147526","definition":"An immunohistochemical result of 2+ for HER2/Neu expression that is considered equivocal for expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66DD6F31-FA4C-12A4-E053-F662850AE423","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"COLBERTM","dateModified":"2023-01-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66DD6F31-FA65-12A4-E053-F662850AE423","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"1+","valueDescription":"HER2/Neu Expression by Immunohistochemistry 1+","ValueMeaning":{"publicId":"6117736","version":"1","preferredName":"HER2/Neu Expression by Immunohistochemistry 1+","longName":"6117736","preferredDefinition":"An immunohistochemical result of 1+ for HER2/Neu expression that is considered negative for expression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HER2/Neu Expression by Immunohistochemistry 1+","conceptCode":"C147525","definition":"An immunohistochemical result of 1+ for HER2/Neu expression that is considered negative for expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66DD6F31-FA71-12A4-E053-F662850AE423","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"COLBERTM","dateModified":"2023-01-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66DD6F31-FA8A-12A4-E053-F662850AE423","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"0","valueDescription":"HER2/Neu Expression by Immunohistochemistry 0","ValueMeaning":{"publicId":"6117737","version":"1","preferredName":"HER2/Neu Expression by Immunohistochemistry 0","longName":"6117737","preferredDefinition":"An immunohistochemical result of 0 for HER2/Neu expression that is considered negative for expression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HER2/Neu Expression by Immunohistochemistry 0","conceptCode":"C147524","definition":"An immunohistochemical result of 0 for HER2/Neu expression that is considered negative for expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66DD6F31-FA96-12A4-E053-F662850AE423","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66DD6F31-FAAF-12A4-E053-F662850AE423","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"Not Done","valueDescription":"HER2/Neu Expression by Immunohistochemistry Not Done","ValueMeaning":{"publicId":"6619155","version":"1","preferredName":"HER2/Neu Expression by Immunohistochemistry Not Done","longName":"6619155","preferredDefinition":"An indication for HER2/Neu expression that it was not evaluated by this means","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8087D757-35C8-48A4-E053-F662850A71AD","latestVersionIndicator":"Yes","beginDate":"2019-01-28","endDate":null,"createdBy":"WINCHC","dateCreated":"2019-01-28","modifiedBy":"ONEDATA","dateModified":"2019-01-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8087D757-35E1-48A4-E053-F662850A71AD","beginDate":"2019-01-28","endDate":null,"createdBy":"WINCHC","dateCreated":"2019-01-28","modifiedBy":"ONEDATA","dateModified":"2019-01-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6117732","version":"1","preferredName":"ERBB2 Gene Immunohistochemical Test Status","preferredDefinition":"This gene plays a role in cellular proliferation and is involved in the oncogenic process through amplification and/or overexpression in several cancers.:A diagnostic test in which an antibody is used to link a cellular antigen specifically to a stain that can be seen with a microscope.:A condition or state at a particular time.","longName":"C17756:C51944:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ERBB2 Gene","conceptCode":"C17756","definition":"This gene plays a role in cellular proliferation and is involved in the oncogenic process through amplification and/or overexpression in several cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Immunohistochemical Test","conceptCode":"C51944","definition":"A diagnostic test in which an antibody is used to link a cellular antigen specifically to a stain that can be seen with a microscope.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66DD6F31-F9F2-12A4-E053-F662850AE423","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66DD6F31-FA03-12A4-E053-F662850AE423","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"WINCHC","dateModified":"2019-01-28","changeDescription":"11/26/18 TT released/CWinch. 3/8/18 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"BRCA_HNEU_EXP_IMUHIST_STAT","type":"USED_BY","context":"CCTG"}],"ReferenceDocuments":[{"name":"Her2/neu expression by immuno","type":"Preferred Question Text","description":"Her2/neu expression by immunohistochemistry","url":null,"context":"CCTG"}],"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66DBDD3D-6AA5-2F95-E053-F662850AB7C1","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"CLOHNES","dateModified":"2023-05-10","changeDescription":"11/26/18 TT released/CWinch. 3/8/18 tt/MA39.","administrativeNotes":"5/10/23 added human readable def per CCTG cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"}}